AUS
NZ
UK
CA
USA
IND
Highlights:
- Akero Therapeutics (NASDAQ:AKRO) is set to release its latest earnings report, with an anticipated loss per share of ($0.98) for the quarter.
- The stock has seen notable price fluctuations, trading between $17.86 and $58.40 over the past year.
- The company's lead drug candidate, efruxifermin (EFX), is in Phase 3 trials for treating metabolic dysfunction-associated steatohepatitis (MASH).
Akero Therapeutics (NASDAQ:AKRO) is preparing to release its latest earnings report before the market opens on March 6. The company is expected to report a quarterly loss per share of ($0.98). This earnings update will provide a closer look at the financial position and operational progress of the company.
Recent stock activity has shown movement within a range of $17.86 to $58.40 over the past year. The stock opened at $47.67 in its most recent session, reflecting changes in market conditions. With a market capitalization of $3.33 billion, the company has maintained financial stability, with a low debt-to-equity ratio of 0.05. Additionally, liquidity remains strong, with current and quick ratios both at 17.25.
Stock Performance and Market Activity
Akero Therapeutics has experienced fluctuations in its share price over the past year. The stock has moved within a significant range, with recent trading activity showing continued movement.
The company maintains a strong financial position, with high liquidity and low debt obligations. These financial factors contribute to its ability to sustain operations while advancing research efforts.
Research and Drug Development
Akero Therapeutics focuses on treatments for metabolic diseases. Its lead drug candidate, efruxifermin (EFX), is currently in Phase 3 clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin is designed to regulate metabolism and reduce cellular stress, addressing a growing medical need.
With ongoing research and clinical trials, the company remains engaged in advancing its drug pipeline. The progress of efruxifermin continues to be a central focus as it moves through the regulatory process.
